ES2970828T3 - Nuevos anticuerpos anti-lam - Google Patents

Nuevos anticuerpos anti-lam Download PDF

Info

Publication number
ES2970828T3
ES2970828T3 ES17750586T ES17750586T ES2970828T3 ES 2970828 T3 ES2970828 T3 ES 2970828T3 ES 17750586 T ES17750586 T ES 17750586T ES 17750586 T ES17750586 T ES 17750586T ES 2970828 T3 ES2970828 T3 ES 2970828T3
Authority
ES
Spain
Prior art keywords
lam
antibody
seq
antibodies
cases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17750586T
Other languages
English (en)
Spanish (es)
Inventor
Abraham Pinter
Deendayal Patel
Alok Choudhary
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Original Assignee
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rutgers State University of New Jersey filed Critical Rutgers State University of New Jersey
Application granted granted Critical
Publication of ES2970828T3 publication Critical patent/ES2970828T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Gram-positive bacteria
    • C07K16/1289Mycobacteriaceae (F)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • G01N33/56933Mycoplasma
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • G01N33/5695Mycobacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/35Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/44Multiple drug resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
ES17750586T 2016-02-10 2017-02-01 Nuevos anticuerpos anti-lam Active ES2970828T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662293406P 2016-02-10 2016-02-10
PCT/US2017/016058 WO2017139153A1 (en) 2016-02-10 2017-02-01 Novel anti-lam and anti-pim6/lam monoclonal antibodies for diagnosis and treatment of mycobacterium tuberculosis infections

Publications (1)

Publication Number Publication Date
ES2970828T3 true ES2970828T3 (es) 2024-05-30

Family

ID=59563993

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17750586T Active ES2970828T3 (es) 2016-02-10 2017-02-01 Nuevos anticuerpos anti-lam

Country Status (10)

Country Link
US (4) US10729771B2 (https=)
EP (2) EP3414573B1 (https=)
JP (4) JP2019506412A (https=)
CN (2) CN110092830B (https=)
AU (2) AU2017218415B2 (https=)
CA (1) CA3013904C (https=)
ES (1) ES2970828T3 (https=)
RU (1) RU2732502C2 (https=)
WO (1) WO2017139153A1 (https=)
ZA (3) ZA201805990B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2970828T3 (es) 2016-02-10 2024-05-30 Univ Rutgers Nuevos anticuerpos anti-lam
US10830760B2 (en) * 2017-12-20 2020-11-10 General Electric Company Device for rapid detection of tuberculosis-lipoarabinomannan (TB-LAM) with enhanced sensitivity
JP2021521462A (ja) * 2018-03-29 2021-08-26 ファウンデーション オブ イノベーティブ ニュー ダイアグノスティクス 抗体または抗体の組み合わせおよび対象の尿試料中のマイコバクテリウム関連抗原の検出のためのその使用
WO2020018806A1 (en) 2018-07-19 2020-01-23 Rutgers, The State University Of New Jersey Methods for dual detection and differentiation of infection by mycobactierum tuberculosis complex and nontuberculous mycobacteria
JP7130045B2 (ja) * 2018-08-31 2022-09-02 富士フイルム株式会社 イムノクロマトグラフキットおよび結核菌の検出方法
CN114341639A (zh) 2019-09-30 2022-04-12 富士胶片株式会社 免疫检查方法及浓缩用夹具
JP7274595B2 (ja) 2019-09-30 2023-05-16 富士フイルム株式会社 イムノクロマトグラフィー
CN111337665A (zh) * 2020-01-16 2020-06-26 卢氏实验室公司 一种用于检测肺结核感染的免疫层析试纸条及其制备方法
WO2021152966A1 (ja) 2020-01-31 2021-08-05 富士フイルム株式会社 イムノクロマトグラフィー
JP7350100B2 (ja) 2020-01-31 2023-09-25 富士フイルム株式会社 イムノクロマトグラフィー
WO2021153127A1 (ja) 2020-01-31 2021-08-05 富士フイルム株式会社 免疫検査方法
CN111153992A (zh) * 2020-02-21 2020-05-15 首都医科大学附属北京胸科医院 结核分枝杆菌lam的单克隆抗体及其用途
EP4178610A4 (en) * 2020-07-07 2024-08-28 The Regents Of The University Of California METHODS FOR DETECTION OF ANTIGENS FROM DIRECT CLINICAL SAMPLES
EP4192429A4 (en) * 2020-08-05 2024-10-09 The Administrators of The Tulane Educational Fund METHOD FOR DETECTING TB IN BODY FLUID SAMPLES
JP7554275B2 (ja) 2020-09-11 2024-09-19 富士フイルム株式会社 検体液の濃縮方法、及び、検体液の検査方法
JP7590441B2 (ja) 2020-09-11 2024-11-26 富士フイルム株式会社 濃縮デバイス、検体液の濃縮方法、検体液の検査方法、及び、検査キット
CN116113826B (zh) 2020-09-11 2026-02-27 富士胶片株式会社 浓缩器件、被检体液的浓缩方法、被检体液的检查方法、及检查试剂盒
WO2022081716A1 (en) * 2020-10-13 2022-04-21 Accubit LLC - Biotechnology Methods of treating iga nephropathy with thiol-containing molecules
EP4263598A4 (en) * 2020-12-15 2025-04-09 Albert Einstein College of Medicine High-affinity mycobacterium tuberculosis capsule-specific human monoclonal antibodies
CN113480659B (zh) * 2021-06-30 2022-10-21 迪比康(上海)生物科技有限公司 人源抗结核分枝杆菌复合群lam单克隆抗体及其制备和应用
CN114984870A (zh) * 2022-03-15 2022-09-02 齐欣 一种重组蛋白质微球及其制备方法和应用
CN117247450B (zh) * 2023-10-10 2025-02-25 广州市雷德生物科技有限公司 一种lam抗体及其应用
CN118178640B (zh) * 2024-03-08 2025-11-21 中国农业大学 含有牛分枝杆菌表面多糖的佐剂及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4636524A (en) 1984-12-06 1987-01-13 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
CA2474701C (en) 1993-11-19 2009-01-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradeable microparticles containing a biologically active agent
US6656508B2 (en) 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
US20010007660A1 (en) 1997-06-04 2001-07-12 Aharona Glatman-Freedman Methods of treating and protecting against tuberculosis using a monoclonal antibody selective for mycobacterium tuberculosis
AU1384199A (en) 1997-11-07 1999-05-31 Chiron Corporation Method for producing igf-1 sustained-release formulations
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6451346B1 (en) 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
US6953593B2 (en) 2000-02-01 2005-10-11 Lipoprotein Technologies, Inc. Sustained-release microencapsulated delivery system
EP1385486A4 (en) 2001-04-18 2006-05-17 Nostrum Pharmaceuticals Inc NEW COATING OF SLOW RELEASE PHARMACEUTICAL COMPOSITION
US7063725B2 (en) 2002-10-21 2006-06-20 Sdgi Holdings, Inc. Systems and techniques for restoring and maintaining intervertebral anatomy
CA2437639C (en) 2003-08-11 2016-07-05 Valera Pharmaceuticals, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
US20050187631A1 (en) 2004-01-27 2005-08-25 Sdgi Holdings, Inc. Prosthetic device
BRPI0513596B8 (pt) * 2004-07-20 2021-07-27 Chemogen Inc método e kit para detectar uma infecção micobacteriana em uma amostra de um indivíduo de interesse por meio da detecção de antígeno micobacteriano
CN101216491B (zh) * 2008-01-08 2012-06-06 广州益善生物技术有限公司 结核分枝杆菌检测液相芯片及其制备方法
EP2242836B1 (en) * 2008-01-28 2015-05-20 Thomas Jefferson University Method of making hybrid cells that express useful antibodies
CA2737667A1 (en) 2008-09-19 2010-03-25 Medimmune, Llc Targeted binding agents directed to cd105 and uses thereof
US8673845B2 (en) * 2009-07-29 2014-03-18 Toagosei Co., Ltd. Carrier peptide fragment and use thereof
SG192047A1 (en) * 2011-01-24 2013-08-30 Univ Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
KR101707291B1 (ko) 2012-02-29 2017-02-15 오쓰까 세이야꾸 가부시키가이샤 항리포아라비노만난 항체 및 당해 항체를 사용한 항산균증의 이뮤노어세이
JO3462B1 (ar) * 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
ES2970828T3 (es) 2016-02-10 2024-05-30 Univ Rutgers Nuevos anticuerpos anti-lam

Also Published As

Publication number Publication date
US20240307535A1 (en) 2024-09-19
US10729771B2 (en) 2020-08-04
US11707525B2 (en) 2023-07-25
EP3414573B1 (en) 2023-11-08
AU2017218415A1 (en) 2018-09-27
JP7813481B2 (ja) 2026-02-13
ZA201805990B (en) 2023-01-25
US12303562B2 (en) 2025-05-20
AU2017218415B2 (en) 2024-05-02
RU2018131622A3 (https=) 2020-04-13
JP2019506412A (ja) 2019-03-07
CN109073649A (zh) 2018-12-21
CA3013904C (en) 2023-12-12
CN110092830A (zh) 2019-08-06
WO2017139153A1 (en) 2017-08-17
CN110092830B (zh) 2023-07-04
RU2018131622A (ru) 2020-03-10
US20200316199A1 (en) 2020-10-08
US11273220B2 (en) 2022-03-15
EP3414573A4 (en) 2019-10-30
JP2023075196A (ja) 2023-05-30
JP2021105034A (ja) 2021-07-26
ZA202209045B (en) 2023-12-20
US20220168420A1 (en) 2022-06-02
BR112018016226A2 (pt) 2019-01-02
JP2024174883A (ja) 2024-12-17
AU2024205286A1 (en) 2024-08-22
EP3414573A1 (en) 2018-12-19
JP7316685B2 (ja) 2023-07-28
US20190038747A1 (en) 2019-02-07
EP4299072A3 (en) 2024-05-01
RU2732502C2 (ru) 2020-09-18
BR112018016226A8 (pt) 2023-10-24
ZA202307912B (en) 2025-11-26
EP4299072A2 (en) 2024-01-03
CA3013904A1 (en) 2017-08-17

Similar Documents

Publication Publication Date Title
ES2970828T3 (es) Nuevos anticuerpos anti-lam
JP7460091B2 (ja) 広域中和抗hiv-1抗体およびその使用方法
TW201623337A (zh) 抗-因子d抗體變異體及其用途
JP6560195B2 (ja) 黄色ブドウ球菌のLukGH(LukAB)毒素を中和する、非常に強力な抗体の生成
CA3093740A1 (en) Anti-il-27 antibodies and uses thereof
JP2017505758A (ja) 黄色ブドウ球菌のlukgh(lukab)毒素に対する抗体及び抗体配列
CN112969711B (zh) 使用克拉扎珠单抗脱敏和改善hla致敏患者中的肾脏移植
CN113194996B (zh) 克拉扎珠单抗用于治疗慢性抗体介导的器官移植物排斥反应
TW202124432A (zh) 使用pd-1軸抑制劑及抗骨膜蛋白抗體治療癌症之方法
CN118126181B (zh) 人和猴交叉种属抗ccr8膜蛋白抗体
WO2022188829A1 (zh) 新型冠状病毒抗体及其用途
BR112018016226B1 (pt) Anticorpo antilipoarabinomanana (anti-lam) monoclonal, kit para detectar um epítopo de lam, método in vitro para diagnosticar uma infecção de tuberculose ativa em um indivíduo e método in vitro de pré-concentração de lam a partir de uma amostra biológica
WO2024148208A1 (en) Antibodies specifically recognizing tnfr2 and compositions and uses thereof
HK40103004A (zh) 广谱中和抗hiv-1抗体及其使用方法
HK40019070A (en) Broadly neutralizing anti-hiv-1 antibodies and methods of use thereof
EA042959B1 (ru) Нейтрализирующие анти-вич-1 антитела широкого спектра действия и способы их применения